



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Editorial Office
✉ research.integrity@frontiersin.org

RECEIVED 04 August 2023

ACCEPTED 04 August 2023

PUBLISHED 15 August 2023

CITATION

Frontiers Editorial Office (2023) Expression of Concern: The immunobiogram, a novel *in vitro* assay to evaluate treatment resistance in patients receiving immunosuppressive therapy. *Front. Immunol.* 14:1272763. doi: 10.3389/fimmu.2023.1272763

COPYRIGHT

© 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Expression of Concern: The immunobiogram, a novel *in vitro* assay to evaluate treatment resistance in patients receiving immunosuppressive therapy

Frontiers Editorial Office*

An Expression of concern on

The immunobiogram, a novel *in vitro* assay to evaluate treatment resistance in patients receiving immunosuppressive therapy

by Portoles JM, Jimenez C, Janeiro D, Lopez-Oliva MO, Ortega-Carrion A, Blaquez D, Arribas L, Gomez C, Diez T, Pascual J and Portero I (2021). *Front. Immunol.* 11:618202. doi: 10.3389/fimmu.2020.618202

With this notice, Frontiers states its awareness of concerns regarding the authorship of “The Immunobiogram, a Novel *In Vitro* Assay to Evaluate Treatment Resistance in Patients Receiving Immunosuppressive Therapy” published on 25 January 2021. Specifically, concerns have been raised that three individuals, Veronica Sánchez Rodríguez, Marianna di Scala, and Javier Dotor, have been excluded from the author list. An investigation was conducted in line with COPE guidelines involving the authors’ institution and the funding body, but unfortunately no conclusion could be reached.

This Expression of Concern was approved by the Chief Editors of Frontiers in Immunology and the Chief Executive Editor of Frontiers. The authors do not agree to this Expression of Concern.